Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
Sponsor: Wake Forest University Health Sciences
Summary
Pediatric cancer survivors have increased infection-related morbidity and mortality. This study will evaluate immune dysfunction following cancer directed systemic therapy completion, with attention to clinical relevance and infection rate in this population compared to healthy siblings, when applicable. The investigators will also restart vaccinations at earlier time points than previously studied, at 3 months post therapy, and will assess whether boosters or revaccination schedules are superior for regaining immunity against potentially serious infections in survivors.
Official title: Immune Function and Response to Vaccination Following Completion of Cancer Directed Systemic Therapy in Pediatric Patients With Cancer
Key Details
Gender
All
Age Range
2 Years - 21 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2022-08-08
Completion Date
2030-10
Last Updated
2026-01-22
Healthy Volunteers
No
Conditions
Interventions
Vaccine
Patients will have lab evaluations for immune function at baseline, 3, 6, 9 and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.
Locations (1)
Levine Cancer Institute
Charlotte, North Carolina, United States